** Contract research firm Charles River Laboratories' CRL.N shares fall 11.1% to $169.01 premarket
** Company forecasts 2025 revenue will decline organically in a similar range as estimated in 2024
** Charles River in November forecast full-year 2024 revenue to decrease 2% to 3%, versus previous expectations of it falling 2.5% to 4.5%
** Company says lower commercial contract drug manufacturing revenue is expected to "reduce consolidated revenue growth by approximately 1% in 2025"
** Charles River says a cell therapy client notified CRL that it would terminate its commercial agreement with the company "to utilize another long-time CDMO partner"
** Company adds that cell and gene therapy client demand "is not as robust as at the time of acquisition, but attractive, long-term growth opportunities exist for its CDMO business"
** Stock fell 21.9% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。